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Abstract
Angiomyolipoma is the most common benign solid renal
neoplasm observed in clinical practice. Once thought to
be a hamartoma and almost always diagnosed by the
imaged-based detection of fat, angiomyolipomas are now
known to consist of a heterogeneous group of neoplasms.
Although all are considered perivascular epithelioid cell
tumors, many display different pathology, imaging fea-
tures, and clinical behavior. The importance of under-
standing this group of neoplasms is emphasized by the
fact that many types of angiomyolipoma contain little to
no fat, and despite being benign, sometimes escape a pre-
operative diagnosis. These types of angiomyolipomas
can all be considered when encountering a renal mass
that is both hyperattenuating relative to renal paren-
chyma on unenhanced CT and T2-hypointense, features
that reﬂect their predominant smooth muscle compo-
nent. We review recent developments and provide a
radiological classiﬁcation of angiomyolipomas that helps
physicians understand the various types and learn how to
both diagnose and manage them.
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Angiomyolipoma is a solid tumor that is encountered
commonly in the kidney in clinical practice [1, 2]. Angi-
omyolipoma is typically a solid ‘‘triphasic’’ tumor com-
posed of varying amounts of three elements: dysmorphic
blood vessels, smooth muscle components, and mature
adipose tissue [1]. Because most angiomyolipomas con-
tain substantial amounts of adipose tissue, it is usually
diagnosed using CT or MRI by identifying imaging fea-
tures of fat cells in the mass [2]. Those that are able to be
diagnosed using imaging have been called ‘‘classic’’ an-
giomyolipomas [2]. While 80% of angiomyolipomas are
sporadic and most of them inconsequential, approxi-
mately 20% are associated with tuberous sclerosis com-
plex (TSC) [10]. Angiomyolipomas may be found also in
patients with lymphangioleiomyomatosis (LAM) [11, 12].
Recent developments have added to our understanding
of renal angiomyolipoma. First, although once considered
a hamartoma, and more recently a choristoma [2, 3],
angiomyolipoma is now considered among the family of
perivascular epithelioid cell tumors (PEComa) [13]. In
addition, recent developments have revealed that there are
different types of renal angiomyolipoma; collectively, they
compose a heterogeneous group of neoplasms with vari-
able pathology, radiology, and clinical behavior. For
example, in addition to the classic angiomyolipoma, it is
now recognized that some triphasic angiomyolipomas, so-
called fat poor angiomyolipoma, contain only small
amounts of fat cells [4, 5], too few to be detected with
imaging, and are sometimesmistaken for renal cancers [6].
A recently described pathological entity called angiomy-
olipoma with epithelial cysts also contains few or no fat
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cells, and is among the groupof fat poor angiomyolipomas
[7, 8]. Although angiomyolipoma is usually benign, a rare,
potentiallymalignant epithelioid angiomyolipoma is listed
separately in the most recent World Health Organization
(WHO) classification of renal tumors [1, 9].
Understanding recent developments and both the
radiological and pathological differences between the types
of angiomyolipoma is important both in clinical practice
and for future research. In this review, we present a radio-
logical classiﬁcation of angiomyolipoma based on speciﬁc
imaging features, and incorporating recent developments
(Table 1). Our classification is consistent with the WHO
classificationof angiomyolipomas [1].However, the current
WHOclassification is basedon findings at pathology alone,
and was derived not with the intent of describing the varied
radiological appearances of angiomyolipomas. Our radio-
logic classification provides what is currently known about
both the pathology and the radiology of renal angiomyo-
lipomas. Knowledge of the imaging appearance of the
various types, particularly as it relates to both their
pathology and clinical behavior, can assist in the diagnosis
and management of these neoplasms.
Angiomyolipoma: a member of the
family of perivascular epithelioid cell
tumors
The term perivascular epithelioid cell tumors (PEComa)
was introduced by Zamboni et al. in 1996 [20]. In 2002
and 2003, two monographs published under the auspices
of the WHO recognized a family of neoplasms with per-
ivascular epithelioid cell (PEC) differentiation and coined
the term, ‘‘PEComa’’ [14]. PEComas are mesenchymal
neoplasms composed of nests and sheets of predomi-
nantly epithelioid and some spindle cells that are associ-
ated with blood vessel walls, and the perivascular
epithelioid cell or ‘‘PEC’’ (a cell that has no known nor-
mal tissue counterpart). Nearly, all PEComas show
immunoreactivity for both melanocytic [Human mel-
anasome B (HMB)-45 and/or melan-A] and smooth
muscle (smooth muscle actin (SMA) and/or desmin)
markers [15]. This family of neoplasms is a group of
morphologically and immunophenotypically similar le-
sions that can arise at a variety of visceral and soft tissue
sites. A subset of the smooth muscle cells in angiomyo-
lipomas are epithelioid in appearance and often arranged
around blood vessels, a feature that is characteristic of a
PEC [3, 15]. Thus, angiomyolipomas belong to the PE-
Coma family that includes also pulmonary lymphangio-
leiomyomatosis and clear cell ‘‘sugar’’ tumor of the lung
[1, 3, 13–16]. PEComas are related to the genetic altera-
tions found in patients with TSC, an autosomal dominant
genetic disease due to losses of TSC1 (9q34) or TSC2
(16p13.3) genes that may have a role in the regulation of
the Rheb/mTOR/p70S6K pathway, which increase pro-
tein synthesis and consequently, cell growth [16].
Triphasic angiomyolipoma
Triphasic angiomyolipoma is a benign mesenchmal tu-
mor composed of varying amounts of dysmorphic blood
vessels, smooth muscle components, and mature adipose
tissue [1]. It occurs sporadically in less than 0.2% of
people [2], typically during the 4th to 6th decade of life,
and exhibits a female preponderance [3]. Triphasic
angiomyolipoma can be divided radiologically into
‘‘classic’’ and ‘‘fat poor subtypes’’ [2].
Classic angiomyolipoma
The hallmark pathology feature of classic angiomyoli-
poma is abundant fat. The term ‘‘fat’’ in this context is
used to refer to one or more fat cells. On ultrasound,
classic angiomyolipoma is almost always markedly
hyperechoic to renal parenchyma, often as hyperechoic
as renal sinus fat [17, 18] (Fig. 1). Since renal cell carci-
noma (RCC) also may be hyperechoic, ultrasound can-
not be used alone to diagnose a classic angiomyolipoma.
An anechoic rim and intratumoral cysts seen in 73% and
31%, respectively, in RCC smaller than 3 cm are sug-
gestive of RCC because these findings are rarely seen in
angiomyolipoma [18]. In addition, acoustic shadowing is
seen in 21–33% of angiomyolipomas smaller than 3 cm
[17, 18] (Fig. 1) and not typically seen in RCC. In spite of
these characteristic findings, a confident diagnosis of a
classic angiomyolipoma requires the identification of fat
using CT or MRI.
The image-based detection of fat often begins with
CT [19]. On unenhanced CT, the presence of regions of
interest (ROI)-containing attenuations less than -10 HU
allows the confident identification of fat (Fig. 1) [19–21].
The CT appearance of a classic angiomyolipoma varies
due to variable amounts of fat, blood vessels, and
smooth muscle components of the neoplasm. These
neoplasms do not contain smooth muscle; they reveal
smooth muscle-like cells (hence the term ‘‘components’’)
which typically stain positive for HMB-45 and smooth
muscle markers. When evaluating angiomyolipomas with
a small amount of fat with CT, the acquisition of thin
(1.5–3 mm) sections and obtaining attenuation mea-
surements using small ROI or even pixel values may be
necessary to detect fat that otherwise would not be de-
tected because of partial volume-averaging [20, 22, 23]
(Fig. 2). In addition, intratumoral hemorrhage may oc-
cur, particularly in tumors larger than 4 cm; the high
attenuation blood may mask the fat, particularly if there
is a small amount, and lead to misdiagnosing a classic
angiomyolipoma as a renal cancer [24].
Other entities may contain fat and thus regions of fat
attenuation. Liposarcoma may contain fat but rarely
originates in the kidney. The major imaging feature that
helps distinguish angiomyolipoma from liposarcoma is
the ‘‘beak sign’’ or a small divot at the interface of the
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mass with the kidney, often accompanied by a feeding
vessel; both signs indicate a renal origin [25–27]. A fat-
containing mass that originates in the kidney is likely an
angiomyolipoma rather than liposarcoma. Identification
of enlarged or bridging vessels, aneurysms, and peri-
nephric hematomas are additional imaging features of
angiomyolipoma that are rarely seen with liposarcoma
[25, 27]. Although rare, Wilms’ tumors and RCC both
may contain fat. Wilms’ tumors are uncommon in adults
[28]. Most reported cases of fat-containing RCC also
contain calcifications; the pathogenesis is thought to be
due to osseous metaplasia leading to marrow fat for-
mation [29, 30]. Since angiomyolipoma rarely contains
calcifications, the presence of calcification and fat should
raise the possibility of RCC. As a result, a confident
diagnosis of an angiomyolipoma requires that a fat-
containing mass not contain calcification. However, non-
calcified, fat-containing RCC has been reported; fat
attenuations in these cases are thought to be due to lipid-
laden macrophages and cholesterol necrosis [31, 32].
Despite these rare exceptions, it is considered appropri-
ate to diagnose an angiomyolipoma with confidence
when a non-calcified, fat-containing renal mass is
encountered in an adult [6]. Other lesions that may
contain fat include teratomas, but these also usually
contain calcifications. Finally, some non-fat containing
lesions may appear to contain fat by engulfing sinus or
perinephric fat [33]. RCC that is treated with ablation
may appear to contain fat because the effects of the
ablation often include a margin that contains peritu-
moral fat [34].
MRI can be used to detect fat cells and diagnose
angiomyolipoma also. Current MR imaging methods
cannot be used to differentiate fat (or lipid) in fat cells
from fat in the cytoplasm of other types of cells. The
diagnosis of the presence of fat is based on the amount of
intra-voxel fat, not necessarily the cell type. For example,
frequency selective (FS) fat suppression generally indi-
cates the presence of fat cells (adipose tissue) [35].
However, when there are cells containing no fat (only
water) in the same voxel as fat cells or other cells con-
taining intracystoplasmic fat, the amount of fat is gen-
erally insufficient to be detected with the FS fat
suppression technique [36, 37]. On the other hand,
chemical shift suppression can be seen when there is a
small amount of fat; this technique relates to the fact that
signal suppression occurs when voxels contain both fat
and water. However, chemical suppression MRI cannot
be used to distinguish fat cells from other types of cells
that contain intracystoplasmic fat. Therefore, chemical
suppression may not be able to be used to distinguish
small amounts of fat cells in an angiomyolipoma from
cells containing intracytoplasmic fat in clear cell RCC
[38]. The pattern of suppression on opposed phase ima-
ges appears to be important. When the signal loss ap-
pears at the border of the mass and the renal
parenchyma, it has been called an ‘‘india ink artifact’’
and is indicative of an angiomyolipoma [37]. However,
renal masses that demonstrate chemical shift suppression
throughout the mass (but do not suppress on FS fat
suppression techniques) can be due to clear cell RCC or
angiomyolipoma with small amounts of fat cells dispersed
Fig. 1. Angiomyolipoma, classic type, in a 61-year-old wo-
man. Ultrasound (A) shows a 4.2-cm right renal mass (arrows)
that is markedly hyperechoic relative to renal parenchyma and
accompanied by acoustic shadowing (arrow heads). Trans-
verse, unenhanced CT image (5-mm sections) shows a right
renal mass (arrows) with fat attenuation (-60 HU).
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throughout the mass. In our experience, such masses are
more often clear cell RCC, but this deserves further
study.
The management of classic angiomyolipoma is con-
servative; most do not grow and remain asymptomatic.
However, some grow slowly, typically at a rate of 5% per
year or 0.19 cm per year [39, 40]. Some angiomyolipomas,
particularly those larger than 4 cm, may bleed spontane-
ously [39, 40]. Thus, although all classic angiomyolipomas
are benign, some form of radiological follow-up may be
indicated, even when they are asymptomatic. Oesterling
et al. [41] proposed an angiomyolipoma management
algorithm based on tumor size and symptoms. For small
(£4 cm) asymptomatic tumors, observation withUS every
12 months is suggested. If the tumor is small and the pa-
tient symptomatic, treatmentwith arterial embolization or
partial nephrectomy can be considered but observation is
often favored in clinical practice. For symptomatic pa-
tients with large tumors, particularly those whose tumors
have bled, treatment is generally recommended. For large
tumors in asymptomatic patients, observation with CT or
US is recommended. However, despite these recommen-
dations, there is no consensus as to which asymptomatic
angiomyolipomas, if any, need imaging surveillance. To
aid in which approach is best, and to better distinguish
those patients at risk for hemorrhage, an aneurysm size of
Fig. 2. Angiomyolipoma, classic type, with small amount of
fat in a 40-year-old man. Transverse, unenhanced CT (A) and
enhanced (B) images (both using 5-mm sections) shows a
3.4-cm left renal mass (arrows) attenuation values that were
measured on unenhanced images were all higher than
-10 HU. When 1.5-mm sections were reconstructed (C), an
attenuation of -25 HU was obtained and the diagnosis of
angiomyolipoma was made. Fat attenuation was identified
only on unenhanced CT.
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5 mm or larger has been found to predict bleeding with a
100% sensitivity and 86% specificity, whereas a tumor size
of 4 cm or larger resulted in sensitivity and specificity of
100 and 38%, respectively [42]. Others have classified an-
giomyolipomas larger than 4 cm into three groups based
on their vascularity at angiography [43]. In this study,
‘‘minimal vascularity’’ was defined as having few, small,
stretched pathological vessels, ‘‘moderate vascularity’’ as
abundant, medium-size, tortuous vessels with or without
small aneurysms (<5 mm), and ‘‘marked vascularity’’ as
multiple, large tortuous vessels with/without large aneu-
rysms (>5 mm) [43]. Angiomyolipomas larger than 4 cm
with minimal vascularity were significantly less likely to
require intervention due to bleeding (14.3%) than those
with marked vascularity (50%) [43]. Renal arterial embo-
lization and partial nephrectomy are typically are used to
treat renal angiomyolipomas. However, renal arterial
embolization carries a complication rate of 10% [44] with a
30% risk of post-embolization syndrome due to an
inflammatory response to necrotic tissue [45], and partial
nephrectomy carries a complication rate of 5–23% [46].
Recently, ablation, using transarterial ethanol, or percu-
taneous ablation (using cryoablation or radiofrequency)
has been introduced as a third option, butmore experience
will be needed to establish its role [47–50].
Fat poor angiomyolipoma
Some triphasic angiomyolipomas contain too little fat
(i.e., too few fat cells) to be detected with unenhanced
CT; some have been diagnosed pre-operatively as RCC
and inadvertently removed at surgery [6]. These subtypes
are now collectively referred to as ‘‘fat poor angiomyo-
lipomas’’ [2]. By definition, these lesions do not reveal fat
at unenhanced CT, even when thin (1.5–3 mm) sections
are used. In 1997, the term ‘‘angiomyolipoma with
minimal fat’’ was introduced to describe angiomyolipo-
mas that were hyperattenuating relative to renal paren-
chyma on unenhanced CT, homogeneously enhancing,
and at pathology were composed almost entirely of a
smooth muscle component and little to no fat [5].
However, this term was used in subsequent studies to
describe all angiomyolipomas in which fat could not be
detected with unenhanced CT [51–53]. We now know
that fat poor angiomyolipomas can be hyperattenuating
or isoattenuating. Therefore, lesions that were described
as angiomyolipomas with minimal fat represented only a
subset of fat poor angiomyolipomas [6]. Furthermore,
several additional studies have used other terms to de-
scribe fat poor angiomyolipomas, including ‘‘angiomy-
olipoma without visible fat on unenhanced CT’’,
‘‘minimal fat angiomyolipoma’’ and ‘‘lipid-poor angio-
myolipoma’’ [54–57]. For the most part, the lesions in
these studies represented fat poor angiomyolipomas, but
the investigators use of different terms may have sug-
gested to some readers that the lesions were different. To
reduce this confusion, and potential communication and
documentation errors regarding angiomyolipomas that
do not reveal evidence of fat cells on unenhanced CT, we
believe the term ‘‘fat poor angiomyolipoma’’ is the most
appropriate [2]. These lesions’ pathology explains the
rationale for the use of this term and also explains why
there are multiple subtypes of fat poor angiomyolipo-
mas.
It has been difﬁcult to deﬁne at pathology the amount
of fat below which the mass would be considered a ‘‘fat
poor angiomyolipoma’’. All such masses have insufﬁ-
cient amounts of fat to be detected by imaging but the
detection of fat depends both on the amount of fat and
its distribution in the mass. An angiomyolipoma may be
overall composed of a certain amount of fat, but the
distribution of fat may be focal, scattered, or diffuse. One
proposed deﬁnition of a fat poor angiomyolipoma is that
the lesion contain no more than 25% fat cells per high
powered ﬁeld (hpf) [4]. However, with this definition, if
all the fat cells were located in one region of the mass, the
fat may be detectable with imaging even though it is ‘‘fat
poor’’ according to this pathology definition. On the
other hand, a pathology definition that includes masses
with a larger percentage of fat cells may consist of masses
that contain fat cells that are scattered and diffusely
distributed and not detectable with imaging. Hence this
hypothetical lesion would not be ‘‘fat poor’’ by pathol-
ogy, yet the fat would not be detectable with imaging.
Despite this limitation, it has been found that most fat
poor angiomyolipomas contain less than 25% fat cells/
hpf, and hence this definition reported in the pathology
literature is one that makes the most sense to adopt in a
radiological classification [4]. Dividing fat poor angio-
myolipomas into three subtypes—hyperattenuating and
isoattenuating angiomyolipomas, and angiomyolipoma
with epithelial cysts—addresses the relationship of the
amount of fat cells and their distribution in the mass [4].
Hyperattenuating angiomyolipoma
Hyperattenuating angiomyolipoma is now the preferred
term to describe a lesion that was originally described as
an ‘‘angiomyolipoma with minimal fat’’; these lesions
represent approximately 4–5% of all angiomyolipomas
Fig. 3. Angiomyolipoma, fat poor type, hyperattenuating
subtype in a 39-year-old woman. Transverse, unenhanced
CT (5-mm sections) demonstrates a 2.9-cm hyperattenuating
(47 HU) right renal mass (arrows) with no regions that mea-
sured less than 30 HU (A). The mass-enhanced homoge-
nously at CT (B) and was hypointense on transverse T2-
weighted image (fast spin-echo, TR:2400, TE:94) (C). Biopsy
specimen showed smooth muscle component (hematoxylin–
eosin stain; original magnification, 9100.) (D), and was po-
sitive for HMB-45 (E: arrows).
b
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[5]. They are typically small and average 3 cm in diam-
eter [5, 58, 59]. At pathology, they generally contain only
4% (range, 3–10%) fat cells [58]. The abundant smooth
muscle component generally stains positive for HMB-45
antigen and smooth muscle markers [5].
Because of the abundant smooth muscle component,
all hyperattenuating angiomyolipomas are hyperattenu-
ating relative to renal parenchyma on unenhanced CT
(usually more than 45 HU) similar to smooth muscle
elsewhere, and typically homogeneously enhancing on
CT [5, 58] (Fig. 3). On MRI, they behave similarly to
smooth muscle and are T1-hypointense, T2-hypointense,
and like CT, often enhance homogeneously [5, 58]
(Fig. 3). Typically, there are no regions that show signal
loss on fat-suppressed pulse sequences and no chemical
shift suppression. On ultrasound, they are usually
homogeneously isoechoic, similar to smooth muscle
elsewhere [5, 59], although one study reported they may
be hyperechoic [58]. In addition to angiomyolipoma,
hyperattenuating, homogeneously enhancing renal mas-
ses can be the result of other entities including RCC
(typically the papillary type), oncocytoma, lymphoma,
metanephric adenoma, leiomyoma, and metastases [6,
60]. In the absence of a malignant tumor elsewhere, the
likely causes of a hyperattenuating renal mass are RCC,
hyperattenuating angiomyolipoma, and oncocytoma. In
one study, only 2% of RCC were hyperattenuating and
homogeneously enhancing, and none was isoechoic [5].
Therefore, when encountering a small (less than or equal
to 3 cm) renal mass that is hyperattenuating on unen-
hanced CT and homogeneously enhancing, a hyperat-
tenuating angiomyolipoma should be considered,
particularly, if it is isoechoic on US or T2-hypointense on
MRI [5, 6, 60, 61]. Percutaneous biopsy is recommended
to provide a confident diagnosis of an angiomyolipoma
[5, 6, 60, 61] (Fig. 3).
Isoattenuating angiomyolipoma
Isoattenuating angiomyolipomas by deﬁnition contain
CT attenuations that are close to renal parenchyma on
unenhanced CT (Fig. 4). In our experience, measured
attenuations are typically between approximately -10
and 45 HU. These masses by definition contain no re-
gions of fat attenuation at unenhanced CT. This type of
angiomyolipoma appears this way because it contains
diffuse, scattered fat cells among the smooth-muscle and
vessel components, too few in one area to be detected
with imaging but sufficient in quantity to lower the
overall attenuation relative to hyperattenuating angio-
myolipomas [7] (Fig. 4). On MRI, like hyperattenuating
angiomyolipomas, they are typically T2-hypointense
(due to their smooth muscle component) [55] (Fig. 4).
Because isoattenuating angiomyolipomas are so rare,
experience regarding their appearance on all MRI pulse
sequences is not fully known; they may or may not show
signal loss on fat-suppressed pulse sequences depending
on the amount and distribution of fat cells in the lesion.
However, it should be recognized that unlike hyperat-
tenuating angiomyolipomas, because there are more fat
cells, isoattenuating angiomyolipomas typically show
chemical shift suppression [55, 62] (Fig. 4). On ultra-
sound, in our experience, these angiomyolipomas are
slightly hyperechoic.
Isoattenuating angiomyolipomas are rare but partic-
ularly problematic as there is no speciﬁc feature that
distinguishes them from RCC and since they are so rare,
there is a paucity of literature on how to distinguish the
two. Both isoattenuating angiomyolipoma and clear cell
RCC can be isoattenuating and enhance at CT [53, 56].
Both can demonstrate suppression at chemical shift MRI
[38]. Clear cell RCC may suppress due to the intracyto-
plasmic lipid in the neoplastic cells; isoattenuating an-
giomyolipomas may suppress due to the scattered, sparse
fat cells. As a result, investigators have attempted to
differentiate this type of angiomyolipoma from RCC
using different quantitative feature analyses [52–57, 62,
63]. Using CT histograms and chemical shift MRI, is-
oattenuating angiomyolipoma, relative to RCC, has been
shown to exhibit a greater quantitative area of negative
CT attenuation and a greater amount of signal loss [52,
62]. However, others have claimed that neither CT his-
tograms nor chemical shift MRI can be used to distin-
guish them from RCC [53, 56, 64, 65]. Patterns of
enhancement have also been analyzed to determine if this
type of angiomyolipoma can be differentiated from clear
cell RCC. Because most RCC demonstrates early
enhancement and rapid washout [66], some have sug-
gested that gradual, or prolonged enhancement on CT is
suggestive of angiomyolipoma [52]. However, others
maintain that most angiomyolipomas show an arterial-
to-delayed enhancement ratio greater than 1.5 [55].
Others have evaluated the usefulness of signal intensity
on T2-weighted imaging; fat poor angiomyolipoma,
including the isoattenuating type, is virtually always T2-
hypointense, and clear cell RCC is typically T2-hyper-
intense [55, 63]. However, papillary RCC is typically T2-
hypointense also [67, 68]. Sasiwimonphan, et al suggested
recently that fat poor angiomyolipoma (including the
isoattenuating type) could be reliably differentiated from
RCC if they were T2-hypointense and demonstrated
markedly early enhancement and subsequent washout
[55].
Another problem with understanding how to diag-
nose isoattenuating angiomyolipoma is that previous
studies included all fat poor angiomyolipomas and hence
included both hyperattenuating and isoattenuating an-
giomyolipomas [52–54, 56, 65]. Also, since the diagnosis
of an isoattenuating angiomyolipoma depends on finding
no regions of fat using 1.5–3-mm thin section CT tech-
nique, some of the reported angiomyolipomas may
not have been fat poor as 5-mm sections were used in
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some patients [52–54, 56, 65]. If thin, 1.5–3-mm sections
had been used, small amounts of fat may have been de-
tected in some lesions. As a result, the frequency of fat
poor angiomyolipomas (especially the isoattenuating
subtype) would be smaller than what has been reported
[mean 6.8 cases/year (20–58 cases/4–7.5 years) in these
studies] [52–54, 56, 65]. Although there is no single fea-
ture that is diagnostic, an enhancing renal mass that is
both T2-hypointense and suppresses on chemical shift
imaging (Fig. 4) should prompt consideration of an is-
oattenuating angiomyolipoma. However, the only non-
surgical way to confirm this diagnosis with confidence is
Fig. 4. Angiomyolipoma, fat poor, isoattenuating subtype in
a 71-year-old woman. Transverse, unenhanced CT (5 mm
sections) demonstrates a 1.8-cm isoattenuating right renal
mass (arrows) with an attenuation of 33HU; no regions
measured less than -6 HU (A). The mass enhanced to an
attenuation of 78HU (B). MRI signal intensity of the tumor was
70 on in-phase image (fast spoiled gradient echo, TR:125,
TE:4.2) (C: arrows), and 39 on opposed phase image (fast
spoiled gradient echo, TR:160, TE:2.0) (D: arrows). The mass
was hypointense on T2-weighted imaging (single shot fast
spin echo, TR:26000, TE:189) (E). Because this enhancing
renal mass was isoattenuating, T2-hypointense, and sup-
pressed on chemical shift MR imaging, isoattenuating angio-
myolipoma was suspected and proven by percutaneous
biopsy. Hemotoxlyin-eosin stain specimen (F) showed
smooth muscle component (arrow) and scattered fat cells
(bold arrows).
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a percutaneous biopsy. Further study will be needed to
determine if this combination of features can be used to
diagnose an isoattenuating angiomyolipoma with suffi-
cient confidence to avoid a biopsy.
Angiomyolipoma with epithelial cysts
Angiomyolipoma with epithelial cysts is another ex-
tremely rare variant of angiomyolipoma that contains
epithelial-lined cysts. They are a type of fat poor angio-
myolipoma because they almost always contain few, if
any, fat cells [69]. Like classic angiomyolipoma, these
lesions are benign and more common in women [7, 8, 69–
71]. Although entrapped dilated renal tubules on
pathology have been described in classic angiomyoli-
poma, it is extremely uncommon for classic angiomyo-
lipoma to contain cystic features by imaging; such
features were found in only 18 patients among five series
[7, 8, 69–71]. In angiomyolipoma with epithelial cysts,
the smooth muscle component predominates, however,
unlike other types, these lesions contain epithelial cysts
and a compact subepithelial stroma. Immunohisto-
chemically, the subepithelial compact stroma and muscle
components stain positive for HMB-45, estrogen and
progesterone receptors, actin and desmin [7, 8].
Imaging ﬁndings of angiomyolipoma with epithelial
cysts are not fully known. One report described one that
was hyperattenuating on unenhanced CT (Fig. 5), T2-
hypointense (both due to its smooth muscle component)
(Fig. 6), and contained a small cyst; the non-cystic por-
tion of the tumor-enhanced homogeneously [69]. An-
other report described a multilocular cystic mass that
contained cystic components separate from the smooth
muscle component [70] (Fig. 6). Since cystic components
are a rare manifestation of angiomyolipoma, RCC
should be considered when a solid mass contains cystic
components. However, if the rest of the mass is hyper-
attenuating on unenhanced CT (Fig. 5), T2-hypointense
(Fig. 6), and homogeneously enhancing, an angiomyoli-
poma with epithelial cysts should be considered also.
Indeed, this entity should be added to the differential
diagnosis of a multilocular cystic mass in an adult along
with a multilocular cystic RCC, multilocular cyst, cystic
nephroma, and a mixed epithelial and stromal tumor
(MEST) [70]. Biopsy may not be diagnostic of a multi-
locular cyst or a cystic nephroma. However, because
both angiomyolipoma with epithelial cysts and MEST
may stain positive for desmin or actin, and RCC does
not, percutaneous biopsy may be helpful in diagnosing a
benign neoplasm [70, 72].
Epithelioid angiomyolipoma
Epithelioid angiomyolipoma is an extremely rare type,
ﬁrst described by Eble et al. [9] in 1997, that is composed
of numerous atypical epithelioid muscle cells. Most of
these tumors contain few or no fat cells [9, 73, 74]. Both
genders are equally affected, and the mean age of diag-
nosis is 38 years [1]. Unlike all other angiomyolipomas,
the epithelioid type is potentially malignant and can be
locally aggressive and metastasize [1]. Approximately
one-third demonstrate local extension or distant metas-
tases at presentation; the larger the tumor, the more
likely it will spread [75]. Histologically, these tumors can
resemble and be misdiagnosed as sarcomatoid or high
grade RCC [1]. However, an epithelioid angiomyolipoma
can be differentiated from RCC by the presence of
immunohistochemistry markers such as melanosome-
associated proteins (HMB-45 antigen, melan-A) and
smooth muscle markers (HHF-35, SMA, and caldesmon)
Fig. 4. Continued
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[9, 73]. In addition, epithelial tumor markers that are
typically positive in RCC such as epithelial membrane
antigen (EMA) and cytokeratins are negative in epithe-
lioid angiomyolipoma [1].
Radiologically, epithelioid angiomyolipomas typi-
cally present as large masses with intratumoral hemor-
rhage and necrosis [76–81] (Fig. 7). They average 7-cm in
size and are typically much larger than fat poor angio-
myolipomas [80]. They, along with triphasic angiomyo-
lipomas, may be accompanied also by a spontaneous
perirenal hematoma [80, 81]. Small foci of fat can be
detected with CT or MRI in some patients [80]. Most
epithelioid angiomyolipomas are hyperattenuating on
unenhanced CT (typically more than 45 HU) and T2-
hypointense due to their epithelioid muscle component
[81]. A recent study reported they can present as heter-
ogeneously or homogeneously enhancing solid masses or
as multilocular cystic masses [81] (Figs. 7, 8). The
amount of described enhancement was variable. Multi-
locular cystic epithelioid angiomyolipoma tends to
Fig. 5. Angiomyolipoma with epithelial cysts in a 60-year-old
man. Transverse, unenhanced CT image (1.5 mm sections)
shows a 2.0-cm left renal mass with central, hypoaattenuating
(5 HU) and a peripheral hyperattenuating (50 HU) compo-
nents (A: arrow). The peripheral component enhanced
(B: arrow). This mass was resected during nephrectomy for
an ipsilateral renal cell carcinoma. Pathology revealed angi-
omyolipoma with an epithelial-lined cyst (C: arrowheads). The
cystic area on pathologic specimencorrespond to the low
attenuation area seen on CT.
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exhibit more hemorrhage than is typically seen with
cystic RCC; sometimes it is massive and can be a clue to
the diagnosis [81].
The preoperative distinction between epithelioid
angiomyolipoma and RCC may not be critical as both
lesions are treated with surgical resection. However, the
mTOR pathway was recently found to be activated in
epithelioid angiomyolipoma [82], and some studies have
reported that mTOR inhibitors, such as sirolimus or
temsirolimus, may represent a better treatment option for
patients with epithelioid angiomyolipoma [83, 84]. Hence
the image-based pre-operative diagnosis of this type of
angiomyolipoma may become important in the future.
Angiomyolipoma in tuberous
sclerosis complex
Angiomyolipomas are observed in 55%–75% of patients
with TSC; most form by the third decade [85]. Relative to
sporadic angiomyolipoma, both genders are affected
equally. Angiomyolipomas in TSC typically present at a
younger age, are more often multiple, larger, and almost
always bilateral (Fig. 9).
Most angiomyolipomas in TSC are histologically
identical to the classic type, however, like other sporadic
forms, they may contain few to no fat cells. Fat poor
angiomyolipomas have been reported to occur in over
one-third of patients with TSC. Fat poor angiomyo-
lipomas in TSC appear the same as those presenting
sporadically except they tend to be larger [35]. Since
RCC can occur in patients with TSC, masses that do not
contain visible fat may require a percutaneous biopsy or
close follow-up [40]. Epithelioid angiomyolipoma and
angiomyolipoma with epithelial cysts are also both seen
in patients with TSC [9]. Angiomyolipomas in patients
with TSC are more likely to have an epithelioid com-
ponent or contain epithelial cysts compared to angio-
myolipomas found sporadically [86].
Relative to the general population, angiomyolipomas
in patients with TSC are more likely to need some form
of treatment. Angiomyolipomas in TSC tend to grow
and be more symptomatic [87]. One study reported TSC-
associated angiomyolipomas grew an average of
1.25 cm/year compared to an average growth rate of
sporadic ones of only 0.19 cm/year [40]. Recurrent
angiomyolipoma bleeding may occur in as many as 43%
of patients with TSC where as sporadic angiomyolipo-
mas typically don’t rebleed [88, 89]. The presence of
multiple angiomyolipomas often leads to multiple bleeds,
and the need for repeated treatments. To avoid the need
for repeated surgery, transcatheter embolization (TCE) is
the preferred treatment in patients with TSC with an-
giomyolipomas that have bled. Although TCE is effec-
tive in controlling hemorrhage in the acute setting, it may
not prevent rebleeding and appears to be of limited value
in the long-term [47]. The mTOR inhibitor sirolimus, by
inhibiting the activation of the mTOR pathway, has been
found to be effective in preventing tumor growth and re-
bleeding in patients with TSC [90].
Angiomyolipoma in
lymphangioleiomyomatosis
Renal angiomyolipomas may also occur in patients with
lymphangioleiomyomatosis (LAM), a rare disease char-
acterized by proliferation of atypical smooth muscle-like
Fig. 6. Angiomyolipoma with epithelial cysts in a 46-year-old
man. Transverse, T2-weighted MR image (fast spin-echo,
TR:4000, TE:92) shows a 2.5-cm multilocular cystic mass
with a hyperintense central component, and hypointense wall
(A, B: arrows) and septa (B: arrowhead). Because of suspi-
cion for renal cell carcinoma, this mass was resected. The
specimen showed angiomyolipoma with epithelial cysts; the
wall contained smooth muscle component.
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cells with associated cystic changes. LAM typically pre-
sents with symptoms related to the destructive cystic
changes in the lungs. The pulmonary disease is progres-
sive and may result in pneumothoraces, chylous pleural
effusions, and respiratory failure. LAM occurs sporadi-
cally or in association with TSC [11]. Sporadic LAM
affects 1 in 400,000 adult females; in TSC, LAM occurs
in 30%–40% of adult females [11] and rarely in males and
children. Although the principal clinical manifestations
are derived from pathology in the lungs, LAM is a
multisystem disorder that in addition to renal angio-
myolipomas, causes abdominal lymphadenopathy, chy-
lous ascites, and large cystic lymphatic masses called
lymphangioleiomyomas [11, 12, 91, 92]. LAM is also
associated with an increased frequency of meningioma.
While inherited mutations of the TSC-1 or TSC-2 genes
cause TSC, acquired (somatic) mutations of either gene
are associated with sporadic LAM [11].
The prevalence of renal angiomyolipomas in sporadic
LAM is 40%–54% when patients with the disease are
Fig. 7. Epithelioid angiomyolipoma in a 21-year-old man.
Transverse, unenhanced CT (5 mm sections) shows a
12.0 cm hyperattenuating right renal mass (A: arrows) that
enhanced heterogeneously (B: arrows). No regions of fat
attenuation could be identified. Hematoxylin–eosin staining
specimens show pleomorphic tumor cells with large hyper-
chromatic nuclei and abundant eosinophilic cytoplasm (C).
The tumor cells were was positive for HMB-45 (D arrows).
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evaluated with abdominal CT [11, 12]. According to a
study that evaluated abdominal findings in 80 patients
with LAM not associated with TSC, renal angiomyo-
lipomas were observed in 43 (54%) patients, enlarged
lymph nodes in 31 (39%), and lymphangioleiomyomas in
13 (16%) [12]. In the same study, CT depicted 76 renal
angiomyolipomas in 40 patients; masses were single in 23
(57%) patients and multiple in 17 (43%) patients. An-
giomyolipomas were 0.2–9.0 cm in diameter (mean,
1.3 cm); 55 (72%) measured less than 1.5 cm in diameter,
while 44 (58%) measured less than 1.0 cm in diameter.
This study also reported a patient with a fat poor angi-
omyolipoma diagnosed by biopsy. Although there are
few reports of angiomyolipomas in patients with LAM
not associated with TSC, they are typically smaller, less
frequently bilateral, and less prone to bleeding than those
found in patients with TSC [11]. While one study re-
ported an epithelioid angiomyolipoma in LAM [93], to
our knowledge, an angiomyolipoma with epithelial cysts
has not been reported in a patient with LAM not asso-
ciated with TSC. The European Respiratory Society
guidelines recommend that patients with unilateral an-
giomyolipomas, no clinical features of TSC, and no
pulmonary symptoms, should be evaluated for LAM by
Fig. 8. Epithelioid angiomyolipomae in a 40-year-old wo-
man. Transverse, unenhanced CT (5-mm sections) (A) and
enhanced CT (B) demonstrates a 5.0-cm multilocular cystic
mass in the left kidney. Both the wall and septa (arrows) were
hyperattenuating (48 HU) and enhanced. On transverse, T2-
weighted MR image (fat-saturated fast spin-echo, TR:3800,
TE: 89) (C), the wall (arrows) and septum (arrowhead) of the
multilocular cystic mass appeared hypointense. On a trans-
verse, T1-weighted MR image (fast spoiled gradient echo,
TR: 150, TE:2.3) (D), the cystic component was hyperintense
(arrows). The mass was considered a Bosniak Category 3
lesion and resected due to its appearance. The hyperin-
tense cystic component corresponded to hemorrhage at
pathology.
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undergoing HRCT of the chest [18]. In patients with
bilateral angiomyolipomas, evaluation for TSC is rec-
ommended via a thorough personal and family history
for manifestations of TSC. If TSC is found, evaluation
for LAM with HRCT of the chest is recommended [11].
As with sporadic angiomyolipoma, the guidelines for
patients with LAM also recommend that asymptomatic
small (<4 cm) renal angiomyolipomas be followed
yearly with ultrasound [11]. Larger angiomyolipomas or
small ones with aneurysms 5 mm or larger in diameter
are thought to be at an increased risk for bleeding, and
hence followed with ultrasound twice yearly to evaluate
for growth. Treatment by renal arterial embolization or
partial nephrectomy can be considered when an angio-
myolipoma bleeds. Recently, two prospective open-label
clinical trials in patients with LAM and angiomyolipoma
found that the mTOR inhibitor sirolimus reduced angi-
omyolipoma volume [90, 94]. However, mTOR inhibi-
tors are not recommended as first-line therapy because
their ability to prevent bleeding has not been evaluated
and side-effects are common [90, 94]. Furthermore, the
relative risks and benefits of treatment with sirolimus
have not been compared to renal arterial embolization or
partial nephrectomy. Embolization is generally recom-
mended, with partial nephrectomy reserved for masses in
which a malignancy is considered. Sirolimus may be
considered in patients with symptomatic angiomyoli-
poma not amenable to embolization or surgery.
Conclusion
Our understanding of the pathology, radiology, and
clinical behavior of angiomyolipoma has matured well
beyond the original ‘‘classic’’ descriptions. The variable
and heterogeneous nature of this neoplasm now consid-
ered among the family of PEComa, is indeed important
to understand in clinical practice. As radiologists,
knowledge of the various types, their imaging appear-
ance, and how they are classiﬁed will help in both diag-
nosis and treatment. Although the detection of fat is a
well-established diagnostic imaging feature of classic
angiomyolipoma, a hyperattenuating appearance on
unenhanced CT and a T2-hypointense appearance at
MRI both correspond to the smooth muscle component,
are important diagnostic clues to the types of angio-
myolipomas that contain few or no fat cells. Because
malignancies can also demonstrate these imaging char-
acteristics, percutaneous biopsy is recommended for
small (less than or equal to 3 cm) hyperattenuating, T2-
hypointense, enhancing renal masses so that unnecessary
surgery can be avoided. When hyperattenuating, T2-
hypointense, enhancing renal masses are larger, or there
is evidence of massive hemorrhage, proceeding directly to
surgery may be appropriate, both to prevent further
bleeding and because both renal cancer and epithelioid
AML are more likely.
Open Access. This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health
Organization classification of tumors: pathology and genetics. Tu-
mors of the urinary system and male genital organs. Lyon: IARC
Press
2. Lane BR, Aydin H, Danforth TL, et al. (2008) Clinical correlates of
renal angiomyolipoma subtypes in 209 patients: classic, fat poor,
tuberous sclerosis associated and epithelioid. J Uro 180:836–843
3. Tamboli P, Ro JY, Amin MB, Ligato S, Ayala AG (2000) Benign
tumors and tumor-like lesions of the adult kidney. Part II: benign
mesenchymal and mixed neoplasms, and tumor-like lesions. Adv
Anat Pathol 7:47–66
4. Milner J, McNeil B, Alioto J, et al. (2006) Fat poor renal angio-
myolipoma: patient, computerized tomography and histological
findings. J Urol 176:905–909
5. Jinzaki M, Tanimoto A, Narimatsu Y, et al. (1997) Angiomyoli-
poma: imaging findings in lesions with minimal fat. Radiology
205:497–502
6. Silverman SG, Israel GM, Herts BR, Richie JP (2008) Management
of the incidental renal mass. Radiology 249:16–31
7. Fine SW, Reuter VE, Epstein JI, Argani P (2006) Angiomyolipoma
with epithelial cysts (AMLEC): a distinct cystic variant of angio-
myolipoma. Am J Surg Pathol 30:593–599
8. Davis CJ, Barton JH, Sesterhenn IA (2006) Cystic angiomyolipoma
of the kidney: a clinicopathologic description of 11 cases. Mod
Pathol 19:669–674
9. Eble JN, Amin MB, Young RH (1997) Epithelioid angiomyoli-
poma of the kidney: a report of five cases with a prominent and
diagnostically confusing epithelioid smooth muscle component.
Am J Surg Pathol 21:1123–1130
10. Williamson B Jr, Bernard FK Jr (2000) Benign neoplasmas of the
renal parenchyma. In: Pollack HM, Mcclennan BL (eds) Clinical
Urogrphy, 2nd edn. Philadelphia: Saunders, pp 1413–1439
11. Johnson SR, Cordier JF, Lazor R, et al. (2010) European Respi-
ratory Society guidelines for the diagnosis and management of
lymphangioleiomyomatosis. Eur Respir J 35:14–26
Fig. 9. Angiomyolipoma in a 32-year-old woman with
tuberous sclerosis complex. Transverse, unenhanced CT (5-
mm sections) shows multiple bilateral renal masses each
containing fat attenuation (less than -10 HU) diagnostic of
angiomyolipomas.
602 M. Jinzaki et al.: Renal angiomyolipoma
12. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J (2000) Lym-
phangioleiomyomatosis: abdominopelvic CT and US findings.
Radiology 216:147–153
13. Zamboni G, Pea M, Martignoni G, et al. (1996) Clear cell ‘‘sugar’’
tumor of the pancreas. A novel member of the family of lesions
characterized by the presence of perivascular epithelioid cells. Am J
Surg Pathol 20:722–730
14. Folpe AL (2002) Neoplasms with perivascular epithelioid differ-
entiation (PEComas). In: Fletcher CDM, Unni KK, Mertens F
(eds) Pathology and genetics of tumours of soft tissue and bone.
Lyon: IARC Press, pp 221–222
15. Hornick JL, Fletcher CD (2006) PEComa: what do we know so far?
Histopathology 48:75–82
16. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F (2008)
PEComas: the past, the present and the future. Virchows Arch
452:119–132
17. Siegel CL, Middleton WD, Teefey SA, McClennan BL (1996)
Angiomyolipoma and renal cell carcinoma: US differentiation.
Radiology 198:789–793
18. Jinzaki M, Ohkuma K, Tanimoto A, et al. (1998) Small solid renal
lesions: usefulness of power Doppler US. Radiology 209:543–550
19. Bosniak MA (1981) Angiomyolipoma (hamartoma) of the kidney:
a preoperative diagnosis is possible in virtually every case. Urol
Radiol 3:135–142
20. Bosniak MA, Megibow AJ, Hulnick DH, Horii S, Raghavendra
BN (1988) CT diagnosis of renal angiomyolipoma: the importance
of detecting small amounts of fat. AJR Am J Roentgenol 151:497–
501
21. Simpson E, Patel U (2006) Diagnosis of angiomyolipoma using
computed tomography-region of interest <or = -10 HU or 4
adjacent pixels <or = -10 HU are recommended as the diag-
nostic thresholds. Clin Radiol 61:410–416
22. Takahashi K, Honda M, Okubo RS, et al. (1993) CT pixel mapping
in the diagnosis of small angiomyolipomas of the kidneys. J
Comput Assist Tomogr 17:98–101
23. Kurosaki Y, Tanaka Y, Kuramoto K, Itai Y (1993) Improved CT
fat detection in small kidney angiomyolipomas using thin sections
and single voxel measurements. J Comput Assist Tomogr 17:745–
748
24. Corr P, Yang WT, Tan I (1994) Spontaneous haemorrhage from
renal angiomyolipomata. Australas Radiol 38:132–134
25. Israel GM, Bosniak MA, Slywotzky CM, Rosen RJ (2002) CT
differentiation of large exophytic renal angiomyolipomas and per-
irenal liposarcomas. AJR Am J Roentgenol 179:769–773
26. Wang LJ, Wong YC, Chen CJ, See LC (2002) Computerized
tomography characteristics that differentiate angiomyolipomas from
liposarcomas in the perinephric space. J Urol 167(2 Pt 1):490–493
27. Ellingson JJ, Coakley FV, Joe BN, et al. (2008) Computed tomo-
graphic distinction of perirenal liposarcoma from exophytic angi-
omyolipoma: a feature analysis study. J Comput Assist Tomogr
32:548–552
28. Parvey LS, Warner RM, Callihan TR, Magill HL (1981) CT
demonstration of fat tissue in malignant renal neoplasms: atypical
Wilms’ tumors. J Comput Assist Tomogr 5:851–854
29. Strotzer M, Lehner KB, Becker K (1993) Detection of fat in a renal
cell carcinoma mimicking angiomyolipoma. Radiology 188:427–428
30. Helenon O, Chretien Y, Paraf F, et al. (1993) Renal cell carcinoma
containing fat: demonstration with CT. Radiology 188:429–430
31. Wasser EJ, Shyn PB, Riveros-Angel M, et al. (2013) Renal cell
carcinoma containing abundant non-calcified fat. Abdom Imaging
38:598–602
32. Richmond L, Atri M, Sherman C, Sharir S (2010) Renal cell car-
cinoma containing macroscopic fat on CT mimics an angiomyoli-
poma due to bone metaplasia without macroscopic calcification. Br
J Radiol 83:e179–e181
33. Helenon O, Merran S, Paraf F, et al. (1997) Unusual fat-containing
tumorsof thekidney: adiagnostic dilemma.Radiographics 17:129–144
34. Schirmang TC, Mayo-Smith WW, Dupuy DE, Beland MD, Grand
DJ (2009) Kidney neoplasms: renal halo sign after percutaneous
radiofrequency ablation–incidence and clinical importance in 101
consecutive patients. Radiology 253:263–269
35. Lemaitre L, Claudon M, Dubrulle F, Mazeman E (1997) Imaging
of angiomyolipomas. Semin Ultrasound CT MR 18:100–114
36. Earls JP, Krinsky GA (1997) Abdominal and pelvic applications of
opposed-phase MR imaging. AJR Am J Roentgenol 169:1071–1077
37. Israel GM, Hindman N, Hecht E, Krinsky G (2005) The use of
opposed-phase chemical shift MRI in the diagnosis of renal an-
giomyolipomas. AJR Am J Roentgenol 184:1868–1872
38. Outwater EK, Bhatia M, Siegelman ES, Burke MA, Mitchell DG
(1997) Lipid in renal clear cell carcinoma: detection on opposed-
phase gradient-echo MR images. Radiology 205:103–107
39. Seyam RM, Bissada NK, Kattan SA, et al. (2008) Changing trends
in presentation, diagnosis and management of renal angiomyoli-
poma: comparison of sporadic and tuberous sclerosis complex-
associated forms. Urology 72:1077–1082
40. Lemaitre L, Robert Y, Dubrulle F, et al. (1995) Renal angiomyo-
lipoma: growth followed up with CT and/or US. Radiology
197:598–602
41. Oesterling JE, Fishman EK, Goldman SM, Marshall FF (1986)
The management of renal angiomyolipoma. J Urol 135:1121–1124
42. Yamakado K, Tanaka N, Nakagawa T, et al. (2002) Renal angi-
omyolipoma: relationships between tumor size, aneurysm forma-
tion, and rupture. Radiology 225:78–82
43. Rimon U, Duvdevani M, Garniek A, et al. (2006) Large renal
angiomyolipomas: digital subtraction angiographic grading and
presentation with bleeding. Clin Radiol 61:520–526
44. Nelson CP, Sanda MG (2002) Contemporary diagnosis and man-
agement of renal angiomyolipoma. J Urol 168(4 Pt 1):1315–1325
45. Bissler JJ, Racadio J, Donnelly LF, Johnson ND (2002) Reduction
of postembolization syndrome after ablation of renal angiomyoli-
poma. Am J Kidney Dis 39:966–971
46. Sooriakumaran P, Gibbs P, Coughlin G, et al. (2010) Angiomyo-
lipomata: challenges, solutions, and future prospects based on over
100 cases treated. BJU Int 105:101–106
47. Takebayashi S, Horikawa A, Arai M, Iso S, Noguchi K (2009)
Transarterial ethanol ablation for sporadic and non-hemorrhaging
angiomyolipoma in the kidney. Eur J Radiol 72:139–145
48. Castle SM, Gorbatiy V, Ekwenna O, Young E, Leveillee RJ (2012)
Radiofrequency ablation (RFA) therapy for renal angiomyolipoma
(AML): an alternative to angio-embolization and nephron-sparing
surgery. BJU Int 109:384–387
49. Byrd GF, Lawatsch EJ, Mesrobian HG, Begun F, Langenstroer P
(2006) Laparoscopic cryoablation of renal angiomyolipoma. J Urol
176(4 Pt 1):1512–1516
50. Prevoo W, van den Bosch MA, Horenblas S (2008) Radiofrequency
ablation for treatment of sporadic angiomyolipoma. Urology
72:188–191
51. Jinzaki M, Silverman SG, Tanimoto A, Shinmoto H, Kuribayashi
S (2005) Angiomyolipomas that do not contain fat attenuation at
unenhanced CT. Radiology 234:311
52. Kim JK, Park SY, Shon JH, Cho KS (2004) Angiomyolipoma with
minimal fat: differentiation from renal cell carcinoma at biphasic
helical CT. Radiology 230:677–684
53. Catalano OA, Samir AE, Sahani DV, Hahn PF (2008) Pixel dis-
tribution analysis: can it be used to distinguish clear cell carcinomas
from angiomyolipomas with minimal fat? Radiology 247:738–746
54. Kim JY, Kim JK, Kim N, Cho KS (2008) CT histogram analysis:
differentiation of angiomyolipoma without visible fat from renal
cell carcinoma at CT imaging. Radiology 246:472–479
55. Sasiwimonphan K, Takahashi N, Leibovich BC, et al. (2012) Small
(<4 cm) renal mass: differentiation of angiomyolipoma without
visible fat from renal cell carcinoma utilizing MR imaging. Radi-
ology 263:160–168
56. Chaudhry HS, Davenport MS, Nieman CM, et al. (2012) Histo-
gram analysis of small solid renal masses: differentiating minimal
fat angiomyolipoma from renal cell carcinoma. AJR Am J
Roentgenol 198:377–383
57. Dillon RC, Friedman AC, Miller FH (2010) MR signal intensity
calculations are not reliable for differentiating renal cell carcinoma
from lipid poor angiomyolipoma. Radiology 257:299–300
58. Hafron J, Fogarty JD, Hoenig DM, et al. (2005) Imaging charac-
teristics of minimal fat renal angiomyolipoma with histologic cor-
relations. Urology 66:1155–1159
59. Trigaux JP, Pauls C, Van Beers B (1993) Atypical renal hamarto-
mas: ultrasonography, computed tomography, and angiographic
findings. J Clin Ultrasound 21:41–44
M. Jinzaki et al.: Renal angiomyolipoma 603
60. Silverman SG, Mortele KJ, Tuncali K, Jinzaki M, Cibas ES (2007)
Hyperattenuating renal masses: etiologies, pathogenesis, and
imaging evaluation. Radiographics 27:1131–1143
61. Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES (2006)
Renal masses in the adult patient: the role of percutaneous biopsy.
Radiology 240:6–22
62. Kim JK, Kim SH, Jang YJ, et al. (2006) Renal angiomyolipoma
with minimal fat: differentiation from other neoplasms at double-
echo chemical shift FLASH MR imaging. Radiology 239:174–180
63. Choi HJ, Kim JK, Ahn H, et al. (2011) Value of T2-weighted MR
imaging in differentiating low-fat renal angiomyolipomas from
other renal tumors. Acta Radiol 52:349–353
64. Davenport MS, Neville AM, Ellis JH, et al. (2011) Diagnosis of
renal angiomyolipoma with hounsfield unit thresholds: effect of size
of region of interest and nephrographic phase imaging. Radiology
260:158–165
65. Simpfendorfer C, Herts BR, Motta-Ramirez GA, et al. (2009)
Angiomyolipoma with minimal fat on MDCT: can counts of neg-
ative-attenuation pixels aid diagnosis? AJR Am J Roentgenol
192:438–443
66. Jinzaki M, Tanimoto A, Mukai M, et al. (2000) Double-phase
helical CT of small renal parenchymal neoplasms: correlation with
pathologic findings and tumor angiogenesis. J Comput Assist To-
mogr 24:835–842
67. Oliva MR, Glickman JN, Zou KH, et al. (2009) Renal cell carci-
noma: t1 and t2 signal intensity characteristics of papillary and
clear cell types correlated with pathology. AJR Am J Roentgenol
192:1524–1530
68. Shinmoto H, Yuasa Y, Tanimoto A, et al. (1998) Small renal cell
carcinoma: MRI with pathologic correlation. J Magn Reson
Imaging 8:690–694
69. Rosenkrantz AB, Hecht EM, Taneja SS, Melamed J (2010) Angi-
omyolipoma with epithelial cysts: mimic of renal cell carcinoma.
Clin Imaging 34:65–68
70. Mikami S, Oya M, Mukai M (2008) Angiomyolipoma with epi-
thelial cysts of the kidney in a man. Pathol Int 58:664–667
71. Armah HB, Yin M, Rao UN, Parwani AV (2007) Angiomyolipoma
with epithelial cysts (AMLEC): a rare but distinct variant of
angiomyolipoma. Diagn Pathol 2:11
72. Adsay NV, Eble JN, Srigley JR, Jones EC, Grignon DJ (2000)
Mixed epithelial and stromal tumor of the kidney. Am J Surg Pa-
thol 24:958–970
73. Park HK, Zhang S, Wong MK, Kim HL (2007) Clinical presen-
tation of epithelioid angiomyolipoma. Int J Urol 14:21–25
74. Warakaulle DR, Phillips RR, Turner GD, Davies D, Protheroe AS
(2004) Malignant monotypic epithelioid angiomyolipoma of the
kidney. Clin Radiol 59:849–852
75. Tsai CC, Wu WJ, Li CC, et al. (2009) Epithelioid angiomyolipoma
of the kidney mimicking renal cell carcinoma: a clinicopathologic
analysis of cases and literature review. Kaohsiung J Med Sci
25:133–140
76. Bharwani N, Christmas TJ, Jameson C, Moat N, Sohaib SA (2009)
Epithelioid angiomyolipoma: imaging appearances. Br J Radiol
82:e249–e252
77. Chen J, Wang P, Wang CJ, et al. (2010) Highly aggressive epithe-
lioid renal angiomyolipoma with a very poor prognosis. Chin Med
J (Engl) 123:765–766
78. Radin R, Ma Y (2001) Malignant epithelioid renal angiomyoli-
poma in a patient with tuberous sclerosis. J Comput Assist Tomogr
25:873–875
79. Hung MS, Chang JH, Chang CP, Tai HL (2005) Massive epithe-
lioid angiomyolipoma of the kidney in a young girl. Int J Urol
12:998–1000
80. Froemming AT, Boland J, Cheville J, Takahashi N, Kawashima A
(2013) Renal epithelioid angiomyolipoma: imaging characteristics
in nine cases with radiologic–pathologic correlation and review of
the literature. AJR Am J Roentgenol 200:W178–W186
81. Tsukada J, Jinzaki M, Yao M, et al. (2013) Epithelioid angiomy-
olipoma of the kidney: radiological imaging. Int J Urol 20:1105–
1111
82. Pan CC, Chung MY, Ng KF, et al. (2008) Constant allelic alter-
ation on chromosome 16p (TSC2 gene) in perivascular epithelioid
cell tumour (PEComa): genetic evidence for the relationship of
PEComa with angiomyolipoma. J Pathol 214:387–393
83. Wolff N, Kabbani W, Bradley T, et al. (2010) Sirolimus and
temsirolimus for epithelioid angiomyolipoma. J Clin Oncol 28:e65–
e68
84. Shitara K, Yatabe Y, Mizota A, et al. (2011) Dramatic tumor re-
sponse to everolimus for malignant epithelioid angiomyolipoma.
Jpn J Clin Oncol 41:814–816
85. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis
complex. N Engl J Med 355:1345–1356
86. Aydin H, Magi-Galluzzi C, Lane BR, et al. (2009) Renal angio-
myolipoma: clinicopathologic study of 194 cases with emphasis on
the epithelioid histology and tuberous sclerosis association. Am J
Surg Pathol 33:289–297
87. Steiner MS, Goldman SM, Fishman EK, Marshall FF (1993) The
natural history of renal angiomyolipoma. J Urol 150:1782–1786
88. Kothary N, Soulen MC, Clark TW, et al. (2005) Renal angiomy-
olipoma: long-term results after arterial embolization. J Vasc Interv
Radiol 16:45–50
89. Lee W, Kim TS, Chung JW, et al. (1998) Renal angiomyolipoma:
embolotherapy with a mixture of alcohol and iodized oil. J Vasc
Interv Radiol 9:255–261
90. Bissler JJ, McCormack FX, Young LR, et al. (2008) Sirolimus for
angiomyolipoma in tuberous sclerosis complex or lymphangiolei-
omyomatosis. N Engl J Med 358:140–151
91. Maziak DE, Kesten S, Rappaport DC, Maurer J (1996) Extra-
thoracic angiomyolipomas in lymphangioleiomyomatosis. Eur
Respir J 9:402–405
92. Kenerson H, Folpe AL, Takayama TK, Yeung RS (2007) Activa-
tion of the mTOR pathway in sporadic angiomyolipomas and other
perivascular epithelioid cell neoplasms. Human Pathol 38:1361–
1371
93. Higa F, Uchihara T, Haranaga S, et al. (2009) Malignant epithe-
lioid angiomyolipoma in the kidney and liver of a patient with
pulmonary lymphangioleiomyomatosis: lack of response to siroli-
mus. Intern Med 48:1821–1825
94. Davies DM, Johnson SR, Tattersfield AE, et al. (2008) Sirolimus
therapy in tuberous sclerosis or sporadic lymphangioleiomyoma-
tosis. N Engl J Med 358:200–203
604 M. Jinzaki et al.: Renal angiomyolipoma
